Eli Lilly's Manufacturing Focus Shifts as Revenue Grows
Eli Lilly (LLY) has shifted its focus from manufacturing capacity expansion for GLP-1 drugs to product launches and acquisitions, signaling a strategic pivot. This change comes amid strong revenue growth and rising stock performance.
Tickers: $AMGN $JNJ $LLY $MRK $PFE
Topics: corporate strategy drug development manufacturing pharmaceuticals